BioSpace News Archive

ValnevaSE announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at the Cowen 43rd Annual Healthcare Conference, to take place in-person March 6 - 8, 2023 in Boston, Massachusetts.

Britannia Life Sciences Inc. (CSE: BLAB) (FSE: L020) (“Britannia” or the “Company”) is pleased to provide its unaudited financial results for the three- and nine-month periods ended December 31, 2022.

Neurolief, a medical neurotechnology company, announces the launch of a new Telehealth Channel to enhance patient access to the Relivion MG migraine therapy.

S-Alpha Therapeutics, Inc. announced that Youngmin Huh, Ph.D., Data Science Leader, will present interim data from clinical trial using its novel, investigational device SAT-001 at Ophthalmology Innovation Summit held on 1st of March 2023, at OIS@SECO, Atlanta, GA, USA.

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the Cowen 43rd Annual Health Care Conference at 9:50 a.m. ET on Wednesday, March 8, 2023.

Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced it will report its financial results from the fourth quarter ended December 31, 2022, after the financial markets close on Wednesday, March 15, 2023.

ClearPoint Neuro, Inc., a global therapy-enabling platform company providing navigation and delivery to the brain, announced financial results for its fourth quarter and full-year ended December 31, 2022.

Standard BioTools Inc., driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – announced that President and Chief Executive Officer Michael Egholm, PhD, will present at the Cowen Health Care Conference on Wednesday, March 8, 2023, at 12:50 p.m. ET.

Conformis, Inc. an orthopedic medical device company that features personalized knee and hip replacement products, announced financial results for the fourth quarter and year ended December 31, 2022.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.